Qorium Becomes Reyva as Cultivated Leather Company Moves Towards Commercial Scale
2.11.2026 11:00:00 CET | Business Wire | Press release
New identity signals the company’s evolution into a standalone material brand for luxury and automotive markets Reyva develops real leather by cultivating bovine collagen from a small sample of animal cells. The new brand brings together advanced biotechnology, leather expertise and a clearer luxury proposition. The company’s team, technology, partnerships and commercial ambition continue under the new name.
Qorium, the company that develops cultivated real leather, today announces that it is becoming Reyva. The new name and identity mark its next stage: moving from a pioneering technology business towards a global material brand built for the exacting standards of the luxury leather sector.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261102661351/en/
Reyva creates beautiful, high-performing real leather. By cultivating leather in uniform sheets, we can move beyond the natural limits of traditional hides, with greater control over its shape, size, thickness and structure. Reyva sample photography by Laurent Stevens
Reyva grows collagen directly from animal cells and cultivates it through a proprietary process to create uniform sheets. The resulting material is then tanned to become real leather, made from the same natural material that gives conventional leather its strength, breathability and durability. It does so without the necessity of raising or slaughtering animals, and with dramatically reduced waste, water and energy demands compared with traditional leather production. Reyva’s process is designed to give brands greater control over thickness, structure, quality and traceability, while eliminating the variability and waste associated with animal hides.
The relaunch gives the company a more distinctive platform for commercial growth while preserving what sits at its core: advanced tissue engineering, deep leather knowledge and a commitment to creating a premium material that can work with established tanning, finishing and manufacturing processes.
The name Reyva brings together “RE,” inspired by reinventing leather, and “VA,” expressing forward movement. It also echoes rey, the Spanish word for “king,” offering a subtle nod to luxury. Reyva is pronounced RAY-vuh, with the emphasis on the first syllable “ray,” as in a ray of light.
“Reyva reflects the company we have become: ambitious, design-led and ready to stand alongside the world’s leading material brands,” said Michael Newton, CEO of Reyva. “Our science gives us a fundamentally new way to make real leather. Our next chapter is about turning that capability into a material that designers and manufacturers choose for its beauty, consistency and performance, as well as its sustainability credentials.”
Reyva’s platform begins with a small, painless biopsy. Selected cells are banked and multiplied before being cultivated in proprietary tissue bioreactors, where they form collagen sheets. These sheets are then tanned and finished using leather-industry craftsmanship and expertise. The material can be cut, stitched, embossed, tanned and finished, and can be engineered to meet the requirements of different applications.
The company is industrialising its process at the Brightlands Maastricht Health Campus in the Netherlands. It is working with selected partners in automotive and luxury fashion as it progresses from development to commercial volumes. Initial availability will be limited, with capacity increasing as the company scales.
“Leather is an extraordinary natural material, but its conventional production begins with the limits and variability of an animal hide,” said Dr Mark Post, co-founder and Chief Science Officer of Reyva. “By cultivating collagen in a controlled environment, we can preserve the qualities people value in leather while introducing a new level of precision, consistency and resource efficiency.”
An independent life-cycle assessment by CE Delft projects that Reyva’s cultivated leather could achieve an 87% lower carbon footprint than conventional cow-derived leather at full-scale production in 2029 using renewable electricity. The assessment calculated 10.5 kg CO₂-equivalent per square metre at the tannery gate, including finishing, compared with a benchmark of 77–83 kg CO₂-equivalent per square metre for conventional French calf leather. Reyva will continue to update its assessment as the process scales and primary data becomes available.
Reyva was founded by tissue-engineering pioneer Dr Mark Post, leather-industry expert Rutger Ploem who comes from a family of tanners spanning six generations, and sustainability entrepreneur Stef Kranendijk. The company is led by CEO Michael Newton and has raised €30 million to date, including a €22 million Series A announced in November 2025.
View source version on businesswire.com: https://www.businesswire.com/news/home/20261102661351/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
NetApp Completes Acquisition of PEAK:AIO to Accelerate Zettabyte-scale AI Deployments2.11.2026 14:00:00 CET | Press release
Acquisition strengthens NetApp Novus, high-performance storage, with differentiated metadata technology and a parallel file architecture purpose-built for AI NetApp® (NASDAQ: NTAP), the Intelligent Data Infrastructure company, today announced that it completed the acquisition of PEAK:AIO, a pioneer in next-generation metadata architecture and high-performance parallel file systems. With this acquisition, NetApp can leverage metadata services and parallel namespace innovations to power the fastest storage on the planet, NetApp Novus, to support zettabyte-scale file systems for the most demanding workloads of AI clouds and GPU-as-a-service providers. For the best AI infrastructure economics, organizations need to keep GPU resources continuously supplied with data without bottlenecks. The acquisition advances NetApp’s strategy for the next phase of AI infrastructure by bringing PEAK:AIO’s metadata and parallel file system expertise together with NetApp ONTAP, giving customers a path to AI
Bentley Systems Announces Seequent’s Acquisition of Seismic Interpretation Software Company Eliis2.11.2026 14:00:00 CET | Press release
Strengthens Seequent’s subsurface software portfolio, energy and geophysics capabilities, and expands team of specialists Bentley Systems, Incorporated (Nasdaq: BSY), the infrastructure engineering software company, today announced that Seequent, The Bentley Subsurface Company, has acquired seismic interpretation software company Eliis. The acquisition will enrich Seequent’s capabilities in geophysics with seismic data interpretation and further advance subsurface understanding to help solve complex global challenges. Eliis’ global team of more than 100 geoscientists, technical specialists, and researchers will join Seequent. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261029964674/en/ 3D view from PaleoScan showcasing recent advancements in seismic interpretation workflows that support prospect evaluation and exploration decision-making Founded in 2007 and with headquarters in Montpellier, France, Eliis develops advanced
HistoSonics Receives Regulatory Approval in Singapore, Advancing Expansion Across Asia-Pacific2.11.2026 14:00:00 CET | Press release
HistoSonics today announced that the company has received market authorization from Singapore’s Health Sciences Authority (HSA) for its Edison® Histotripsy System (under the device name HistoSonics Histotripsy System), marking another significant milestone in the company’s continued international expansion and creating new opportunities to advance access to histotripsy throughout the Asia-Pacific region. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261102090757/en/ HistoSonics Edison® Histotripsy System The Edison System is a novel, non-invasive, image-guided platform that uses the mechanical properties of focused ultrasound, known as histotripsy, to mechanically destroy and liquefy unwanted tissue and tumors. The technology offers a fundamentally new approach to tissue destruction without the need for invasive procedures, radiation, or thermal energy. The Edison System is currently authorized for the destruction of liver
NIQ Publishes 2026 ESG Progress Report, Highlighting Action Across Climate, People, Communities, and Responsible AI2.11.2026 12:45:00 CET | Press release
Report details NIQ’s continued focus on responsible business, including its first climate risk assessment, expanded employee development and more than 100,000 volunteer hours NIQ (NYSE: NIQ), a leading consumer intelligence company, today released its 2026 Environmental, Social and Governance (ESG) Progress Report, detailing the company’s progress on key ESG priorities throughout 2025. The report covers NIQ’s efforts across environmental responsibility, its people and communities, data integrity, and responsible AI. Key highlights from 2025 include:Strengthened its approach to climate risk and environmental measurement: NIQ conducted its first climate risk assessment aligned with Task Force on Climate-related Financial Disclosures (TCFD) recommendations, tracked Scope 1, 2 and 3 emissions under the GHG Protocol, and externally verified its carbon footprint. Invested in associate development, engagement and well-being: Internal mobility increased to 35%, up from 30%, while performance r
Agenus Announces Nature Medicine Publication of Multicenter UNICORN Phase 2 Trial Demonstrating Deep Responses with Neoadjuvant BOT+BAL in Resectable Colon Cancer2.11.2026 12:42:00 CET | Press release
In pMMR/MSS colon cancer, neoadjuvant BOT+BAL met the trial’s primary endpoint with a 36% major pathologic response rate, including 29% pathologic complete response, within an overall 71% pathologic response rate after one BOT dose and two BAL dosesNo patients treated with BOT+BAL had their cancer return, with median follow-up of 19.2 months in MSS disease and 16.7 months in MSI-H disease; 12-month event-free survival was 100% in both combination cohorts.Independent, multicenter UNICORN findings reinforce the NEST peer-reviewed neoadjuvant evidence supporting Agenus’ planned Phase 3 ROBBIN trial in curative-intent MSS/pMMR colon cancer Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced the peer-reviewed publication of results from the investigator-sponsored, multicenter Phase 2 UNICORN trial evaluating short-course preoperative, or neoadjuvant, botensilimab (BOT), Agenus’ multifunctional, Fc-enhanced anti-CTLA-4 antibody, alone or in combination with ba
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom